A Phase I-II Study to Determine the Safety, Pharmacokinetics and Potential Efficacy of Intravenous Administration of SB-743921 on Days 1 and 15 of a 28-Day Dosing Schedule in Patients With Non-Hodgkin Lymphoma and Hodgkin Lymphoma
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Phase 1: Determination of Dose-Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD) first without and then with administration of prophylactic G-CSF.
28 days
Yes
Owen O'Connor, M.D./Ph.D.
Principal Investigator
Columbia University
United States: Food and Drug Administration
CY 2121
NCT00343564
April 2006
July 2010
Name | Location |
---|---|
Herbert Irving Comprehensive Cancer Center | New York, New York 10032 |
Hackensack University Medical Center | Hackensack, New Jersey 07601 |
University of North Carolina | Chapel Hill, North Carolina 27599 |
Cornell University Medical Center | New York, New York 10021 |
Memorial Sloan-Kettering Caner Center | New York, New York 10021 |
Sarah Cannon Cancer Research Institute | Nashville, Tennessee 37203 |